Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
J Am Acad Dermatol. 2019 Sep;81(3):709-716. doi: 10.1016/j.jaad.2019.04.055. Epub 2019 May 2.
Psoriasis and biologic therapies have been associated with psychiatric illnesses.
To determine if persons with psoriasis or those exposed to biologics are more likely to develop a psychiatric illness.
Retrospective electronic medical records cohort study.
Individuals with psoriasis were significantly more likely to have a history of several medical (eg, cardiovascular illnesses) and psychiatric (eg, depression, suicide) illnesses than those without psoriasis. Those with psoriasis who were prescribed a biologic therapy were significantly less likely than those with psoriasis not prescribed a biologic agent to receive a psychiatric illness diagnosis (hazard ratio for any psychiatric illness 0.52, 95% confidence interval 0.51-0.53, P < .0001). With respect to any psychiatric illness, this finding was confirmed when comparing biologic therapy versus methotrexate treatment (0.80, 95% confidence interval 0.76-0.84, P < .0001).
These findings were likely attributable to treatment selection bias.
Individuals with psoriasis have an increased risk of several medical and psychiatric illnesses. Individuals with psoriasis prescribed biologic agents are less likely than those not prescribed biologic agents to develop psychiatric illnesses. Most likely because of treatment selection, individuals with psoriasis prescribed biologic therapy are not currently at increased risk of a psychiatric outcome.
银屑病和生物疗法与精神疾病有关。
确定患有银屑病或接触过生物制剂的人是否更有可能患上精神疾病。
回顾性电子病历队列研究。
与没有银屑病的人相比,患有银屑病的人更有可能患有多种医学疾病(如心血管疾病)和精神疾病(如抑郁、自杀)。与未接受生物制剂治疗的银屑病患者相比,接受生物治疗的银屑病患者被诊断出患有精神疾病的可能性显著降低(任何精神疾病的风险比为 0.52,95%置信区间为 0.51-0.53,P<0.0001)。对于任何精神疾病,与接受甲氨蝶呤治疗相比,这一发现得到了证实(0.80,95%置信区间为 0.76-0.84,P<0.0001)。
这些发现可能归因于治疗选择偏倚。
患有银屑病的人患多种医学和精神疾病的风险增加。与未接受生物制剂治疗的患者相比,接受生物制剂治疗的银屑病患者发生精神疾病的可能性较低。最有可能是由于治疗选择,目前接受生物治疗的银屑病患者没有增加患精神疾病的风险。